There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aerie Pharma (AERI), Rigel (RIGL) and AnaptysBio Inc (ANAB) with bullish sentiments.
Aerie Pharma (AERI)
H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Aerie Pharma today and set a price target of $64. The company’s shares closed yesterday at $38.25, close to its 52-week low of $32.18.
Livnat observed:
“We believe the Street is overreacting to a $1.5M Rhopressa miss, which can largely be explained by value-per-Rx more quickly dropping to where management always said it would go, and a likely temporary moderation of Rx trends. We understand the sequential revenue decline is optically challenging, but substantially higher Medicare coverage just kicked in, and management indicates that wholesaler pull-through shipments have already popped above the recent trend (which we should see in the next investor deck, followed by lagged Rx data). With a new mechanism of action, once-daily adjunctive therapy utility, and competitive pricing, we can’t see a scenario where Rhopressa is done growing after just three quarters on the market.”
According to TipRanks.com, Livnat is a 4-star analyst with an average return of 11.2% and a 50.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Collegium Pharmaceutical.
Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $77.75, which is a 103.3% upside from current levels. In a report issued on April 26, Mizuho Securities also maintained a Buy rating on the stock with a $77 price target.
See today’s analyst top recommended stocks >>
Rigel (RIGL)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Rigel today and set a price target of $8. The company’s shares closed yesterday at $2.32, close to its 52-week low of $1.96.
Pantginis said:
“Valuation and impediments to achieving price target. We reiterate our Buy rating and $8.00 price target. Our price target is based on our clinical net present value (NPV) model, which derives its value from Tavalisse without any current contribution from pipeline assets. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -2.4% and a 36.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
Rigel has an analyst consensus of Strong Buy, with a price target consensus of $7.25, implying a 212.5% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $7 price target.
AnaptysBio Inc (ANAB)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AnaptysBio Inc, with a price target of $126. The company’s shares closed yesterday at $72.29.
Fein wrote:
“Our 12-month price target of $126/share is based on an equally weighted composite of (a) $96/share, as a 35x multiple of taxed and diluted FY32 GAAP EPS of $29.43 discounted back to and (b) an NPV of $155/ share (discount rate 12.0%, growth rate 2.0%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.3% and a 43.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio Inc with a $131.25 average price target, implying an 81.6% upside from current levels. In a report issued on May 3, Cantor Fitzgerald also maintained a Buy rating on the stock with a $140 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
